Skip to Main Content

Paper Details

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Neuro Oncol
285
2018
CAR T cells, CAR T-cell, CAR T-cell product, CAR molecules, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T cells, EphA2, GBM, Glioblastoma, HER2, IL13R2, PDXs, T-cell, T-cell product, Trivalent, Trivalent CAR T cells, UCAR T cells, ephrin-A2, glioblastoma, glioma, human, human epidermal growth factor receptor 2, interleukin-13 receptor subunit alpha-2, patient, patients, primary, primary malignant brain cancer, trivalent T-cell product, tumor, tumor cells, tumors, universal (U) tricistronic transgene
Author NameAffiliation
Pavel Sumazin
Pavel SumazinTexas Children's Hospital, Baylor College of Medicine
Pavel SumazinBaylor College of Medicine
Meenakshi HegdeCenter for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine
Meenakshi Hegde
Meenakshi HegdeTexas Children's Hospital, Baylor College of Medicine
Meenakshi HegdeBaylor College of Medicine
Nabil AhmedCenter for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine
Nabil Ahmed
Nabil AhmedTexas Children's Hospital, Baylor College of Medicine
Nabil AhmedChildren's Cancer Hospital of Egypt
Nabil AhmedBaylor College of Medicine
  • 1 - 12

Datasets

Release 1.2